1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

Search for publications

Only original articles, editorials, guidelines.

  • Coucelo M, Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Soria E, Bilbao C, de la Torre EP, Amorim ML, Mirales A, Cionfrini A, Simões AT, Oliveira AC, Rodríguez-Veiga R, Lloret-Madrid P, Mendizábal Y, Botella C, Bernal T, Bergua J, Algarra L, Tormo M, Sarmento-Ribeiro AB, Trigo F, Cortesão E, Martínez-Sánchez P, Serrano J, Alonso-Domínguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Abuín A, Martínez-López J, Calasanz MJ, García-Sanz R, Gutiérrez N, Pérez-Simón JA, Gómez Casares MT, Sánchez-Garcia J, Montesinos P, Barragán E.

    Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories.

    LEUKEMIA RESEARCH . 160: 108149-108149.

    [doi:10.1016/j.leukres.2025.108149]

  • Domínguez-Ruiz M, Chico JL, López-Marín L, Stanescu S, Crujeiras P, Rodrigues D, Heras-Alonso ML, Torremocha R, Meijón-Ortigueira MDM, Muñoz-Díez P, Lanza VF, Colón C, Villarrubia J, Belanger A, Castillo FJD.

    Abnormal Splicing of GALC Transcripts Underlies Unusual Cases of Krabbe Disease

    Biomedicines . 13(12): .

    [doi:10.3390/biomedicines13123114]

  • Cedena MT, Puig N, Paiva B, de la Puerta Rueda JE, Pérez-Montaña A, Casanova M, Breña Atienza J, Garcia A, de Arriba F, Martínez-Chamorro C, Sirvent M, Blanchard MJ, Alonso Fernández R, Alvarez Rivas MA, Capote FJ, García-Sánchez R, Pérez JJ Sr, Rodriguez-Otero P, Lahuerta JJ, Martínez-López J, Mateos MV, San-Miguel JF.

    Real-world evidence of measurable residual disease assessment in multiple myeloma.

    Blood Advances . : .

    [doi:10.1182/bloodadvances.2025018454]

  • Martin-Moro F, Bento L, Marquet J, Browne-Arthur SF, Gutierrez A, Diaz-Lopez A, Sanchez-Pina J, Garcia-Vela JA, Salar A, Cordoba R, Novelli S, Rodriguez-Salazar MJ, Gonzalez De Villambrosia S, Del Campo R, Luzardo HD, Garcia D, Garcia-Marco JA, Sancho JM, Abrisqueta P, Martin A, Grande C, Lopez-Jimenez J, Bastos-Oreiro M.

    Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI

    ESMO open . 10(12): 105873-105873.

    [doi:10.1016/j.esmoop.2025.105873]

  • Luttwak E, Nemirovsky D, Devlin SM, Boardman AP, Cassanello G, Corona M, Luan D, Dahi PB, Abia AL, Falchi L, Landego I, Lin RJ, Lue JK, Palomba LM, Park JH, Raj SS, Rejeski K, Rivas Delgado A, Scordo M, Tomas AA, Shah GL, Perales MA, Salles G, Shouval R.

    Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

    Hemasphere . 9(11): .

    [doi:10.1002/hem3.70248]

  • Deschênes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, Marcus R, Avigdor A, Ballweg A, Rabinovich E, Alhomoud M, Rivas-Delgado A, Corona De Lapuerta M, Luna De Abia A, Palomba ML, Shah GL, Lin RJ, Boardman AP, Falchi L, Lue JK, Salles GA, Perales MA, Shouval R, Dahi PB, Scordo M.

    Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

    Blood Advances . 9(21): 5571-5584. Number of citations: 1

    [doi:10.1182/bloodadvances.2025016778]

  • Corona M, Brown S, Rejeski K, Flynn JR, Devlin SM, Raj S, Luna de Abia A, Lin RJ, Scordo M, Shah GL, Palomba ML, Boardman AP, Falchi L, Lue J, Salles G, Park J, Giralt SA, Perales MA, Shouval R, Dahi PB.

    Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

    BONE MARROW TRANSPLANTATION . : .

    [doi:10.1038/s41409-025-02745-5]

  • Sobrini-Morillo P, Corral-Tuesta C, Sánchez-Castellano C, Gutiérrez-Blanco T, Blanchard-Rodríguez MJ, Escudero-González B, Nieto-Góngora C, Moujir López J, Serra-Rexach JA, Cruz-Jentoft AJ.

    Sarcopenia in Older Patients with Newly Diagnosed Multiple Myeloma

    Gerontology . : 1-10.

    [doi:10.1159/000549514]

  • Alfonso-Pierola A, Martinez-Cuadrón D, Rodríguez-Veiga R, Gil C, Martínez-Sánchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, García-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Pérez-Simon JA, Rodríguez-Medina C, Bass-Maturana MF, López-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Pérez-Encinas M, Barrios-García M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Durán A, Valero-Nuñez M, Casado-Calderón S, Balerdi A, Torres V, Fernández R, Noriega V, Stevenazzi M, Labrador J, León-Maldonado P, de Rueda-Ciller B, Arce-Fernández O, Amigo ML, Raposo-Puglia JÁ, Solé M, Boluda B, Ayala R, Barragán E, Montesinos P.

    Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

    Leukemia . 39(11): 2686-2696.

    [doi:10.1038/s41375-025-02744-x]

  • Lahuerta JJ, San-Miguel JF, Jiménez-Ubieto A, Alonso Fernández R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernandez M, Ríos-Tamayo R, Oriol A, Blanchard MJ, Carrillo-Cruz E, Martínez-Martínez R, Bargay J, Sureda A, de la Rubia J, Hernandez Garcia MT, Cabañas V, Casado Montero LF, Palomera Bernal L, Gonzalez-Montes Y, Martínez-López J, Rodriguez-Otero P, Krsnik I, Arguiñano JM, Gonzalez-Garcia ME, Ocio EM, de la Cruz J, Mateos MV, Rosiñol L, Bladé J.

    High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

    Blood . 146(15): 1747-1758. Number of citations: 2

    [doi:10.1182/blood.2025028313]

  • Asensi-Díaz E, Barbero Del Olmo L, Urrutia P, Lario A, Gómez-G de la Pedrosa E, García-Ruiz de Morales AG, Martín-Dávila P, Fortún J.

    When Fungal Prophylaxis Fails: A Rare Case of Rhodotorula mucilaginosa Fungemia with Suspected Abdominal Origin

    JOURNAL OF FUNGI . 11(10): . Number of citations: 1

    [doi:10.3390/jof11100723]

  • Encinas C, Blanchard MJ, Fernández RA, Hernández-Rivas JÁ, Tamayo RR, Machado-Vílchez M, Martínez-López J, Mateos MV.

    Factors Increasing the Risk of Infection in Patients With Multiple Myeloma: From Biology to Prevention

    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA . 25(10): .

    [doi:10.1016/j.clml.2025.06.012]

  • Mataix M, Illera N, Hidalgo I, Arriba MDC, Martín E, Fernández G, González C, Larcher F, González VM, Rio MD, Jiménez F, Carretero M.

    Targeting olfactory receptor OR2AT4: An innovative aptamer-based treatment for hair growth promotion

    MOLECULAR THERAPY NUCLEIC ACIDS . 36(3): 102608-102608.

    [doi:10.1016/j.omtn.2025.102608]

  • Sobrini-Morillo P, Corral-Tuesta C, Sánchez-Castellano C, Gutiérrez-Blanco T, Palomo-Rumschisky P, Álvarez-Pinheiro CG, Blanchard-Rodríguez MJ, Serra-Rexach JA, Cruz-Jentoft AJ.

    Comprehensive Geriatric Assessment of Older Patients with Multiple Myeloma: A Prospective Observational Study

    Cancers . 17(17): .

    [doi:10.3390/cancers17172904]

  • Giménez E, Cadenas IG, Piñana JL, Albert E, Vázquez L, Avendaño A, Cabrero M, Esquirol A, Martino R, López-Jiménez J, Cuesta MÁ, Humala K, Villar S, Rovira M, Heras I, Zudaire T, Arroyo I, Zabalza A, Aguado B, Solano C, Navarro D.

    Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study.

    TRANSPLANT INFECTIOUS DISEASE . 27(5): .

    [doi:10.1111/tid.70080]

  • Mauro MJ MD, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes J, Abdo A, Fogliato LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz-Abad N, Dhamal V, Rea D.

    Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.

    Blood Advances . 9(16): 4248-4259. Number of citations: 7

    [doi:10.1182/bloodadvances.2025016042]

  • Cassanello G, Luttwak E, Brown S, Devlin SM, Imber B, Ip A, Leslie LA, Accav NG, Avigdor A, Marcus R, Beyar-Katz O, Corona M, Luna de Abia A, Calabrese De Feo J, Rivas Delgado A, Lue JK, Grommes C, Shah GL, Park J, Perales MA, Salles G, Shouval R, Scordo M, Palomba ML.

    Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience

    BRITISH JOURNAL OF HAEMATOLOGY . 207(2): 525-534. Number of citations: 2

    [doi:10.1111/bjh.20234]

  • Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J.

    Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3,-label, multicentre, randomised clinical trial

    LANCET HAEMATOLOGY . 12(8): 588-598. Number of citations: 1

    [doi:10.1016/S2352-3026(25)00143-7]